Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02603614 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Cenderitide in Chronic Stable Heart Failure With Moderate Renal Impairment
A Phase 1 study, sponsored by Capricor.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT02603614: Completed Phase 1 study, sponsored by Capricor.
NCT02603614 is a Phase 1 study that has completed, run by Capricor. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02603614, a Phase 1 study, has completed, sponsored by Capricor.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
CNDP-578-02 is a randomized, double-blind, placebo-controlled, dose-escalation, crossover design trial. Eight evaluable subjects (n=8) with chronic stable heart failure and moderate renal impairment will be randomized (1:1) to receive cenderitide or placebo. Enrolled subjects will begin with Infusion Period A where they will receive up to 7 days of continuous, subcutaneous, dose-escalating infusions of cenderitide or placebo via the Insulet Drug Delivery System. Enrolled subjects will then cross over into Infusion Period B where they will receive up to 7 days of continuous, subcutaneous, dose-escalating infusions of cenderitide or placebo.
Interventions
- DRUG Placebo
- DRUG Cenderitide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-12 |
| Est. Completion | 2016-03-31 |
| Phase | Phase 1 |
What the finished NCT02603614 record still lists
NCT02603614 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02603614 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02603614 about?
NCT02603614 is a clinical study titled "Safety Study of Cenderitide in Chronic Stable Heart Failure With Moderate Renal Impairment". CNDP-578-02 is a randomized, double-blind, placebo-controlled, dose-escalation, crossover design trial. Eight evaluable subjects (n=8) with chronic stable heart failure and moderate renal impairment will be randomized (1:1) to receive cenderitide or placebo. Enrolled subjects will begin with Infusio...
What is the current status of trial NCT02603614?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2015-12. Estimated completion is 2016-03-31.
What interventions are being tested in trial NCT02603614?
The interventions under investigation include: Placebo (DRUG), Cenderitide (DRUG).
Who is sponsoring clinical trial NCT02603614?
This trial is sponsored by Capricor, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02603614's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia